XL418 is a novel anticancer compound.
- Mechanism
- Curator reviewed
XL418 is a small molecule that inhibits the activity of protein kinase B (PKB or AKT) and S6 Kinase (S6K), which act downstream of phosphoinosotide-3 kinase (PI3K). Activation of these kinases is a frequent event in human tumors, promoting cell growth, survival, and resistance to chemotherapy and radiotherapy. Inactivation of the pathway through inhibition of AKT is expected to induce apoptosis (programmed cell death) in tumor cells. AKT inhibitors may also sensitize tumor cells to a wide range of chemotherapy.
- Primary indication
- CancerCurator reviewed
- Code names
- XL418
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with XL418, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account